Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Jefferies Healthcare Conference
Presentation date: Wednesday, June 8, 2022
Presentation time: 2:30 PM ET
Location: Marriott Marquis, New York, NY
Goldman Sachs 43rd Annual Global Healthcare Conference
Dates: June 13-16, 2022
1x1 meetings only
Location: Terranea Resort, Ranch Palos Verdes, CA
JMP Securities Life Sciences Conference
Fireside Chat date: Thursday, June 16, 2022
Presentation time: 11:00 AM ET
Location: The Lotte New York Palace Hotel, New York, NY
Stifel’s 2022 Virtual Cell Therapy Summit
Dates: June 29-30, 2022
Live webcasts and archived replays of key presentations will be available on the Company's website at https://ir.vorbio.com/news-and-events/events-and-presentations.
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Investors & Media
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.23 |
Daily Change: | 0.02 0.68 |
Daily Volume: | 1,859,520 |
Market Cap: | US$278.040M |
July 21, 2025 June 25, 2025 June 25, 2025 March 20, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load